Summary of Significant Accounting Policies - Additional Information (Detail)			3 Months Ended	12 Months Ended
	Jan. 01, 2022 USD ($)	Apr. 10, 2020 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2021 USD ($) Distributor Contract	Dec. 31, 2020 USD ($)	Aug. 31, 2019 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Proceeds from loans					$ 4,873,000
Accretion or amortization				$ 500,000	$ 0
Allowance for credit losses on held-to-maturity securities				$ 0
Number of wholesale distributors | Distributor				3
Percentage of gross sales from major wholesale distributors				80.00%	86.00%
Allowance for accounts receivable				$ 800,000
Percentage of sales from major customers collaborations and services				95.00%
Asset impairment				$ 100,000
ASU 2020-06
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle accounting standards update adopted				true
Change in accounting principle accounting standards update adoption date				Jan. 01, 2021
Change in accounting principle accounting standards update immaterial effect				true
Commitment Asset | Other Expense
Summary Of Significant Accounting Policies [Line Items]
Asset impairment			$ 1,900,000
MidCap Credit Facility
Summary Of Significant Accounting Policies [Line Items]
Commitment asset						$ 1,500,000
Other asset						$ 400,000
Milestone Rights Liability | Deerfield
Summary Of Significant Accounting Policies [Line Items]
Contingent liability remain payable				$ 65,000,000.0
Vertice Pharma LLC
Summary Of Significant Accounting Policies [Line Items]
Allowance for accounts receivable				$ 800,000
United Therapeutics Corporation
Summary Of Significant Accounting Policies [Line Items]
Percentage of collaborations and services accounts receivables				100.00%
Paycheck Protection Program Loan, CARES Act
Summary Of Significant Accounting Policies [Line Items]
Proceeds from loans		$ 4,900,000
Convertible Promissory Note | Thirona Bio, Inc.
Summary Of Significant Accounting Policies [Line Items]
Investment securities				$ 3,000,000.0
Proceeds from investment securities				$ 3,000,000.0
Maturity date				Dec. 31, 2023
Interest rate				6.00%
Convertible Promissory Note | Subsequent Event | Thirona Bio, Inc.
Summary Of Significant Accounting Policies [Line Items]
Investment securities	$ 5,000,000.0
Proceeds from investment securities	$ 5,000,000.0
AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Percentage of accounts receivable from major wholesale distributors				79.00%	90.00%
Insulin
Summary Of Significant Accounting Policies [Line Items]
Loss on purchase commitments				$ 82,800,000	$ 95,300,000
Loss on purchase commitments, number of new contracts recognized | Contract				0
Minimum | AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months				6 months
Maximum | AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months				12 months